(Q37953243)

25 August 2017

title

Recent advances in the treatment of lupus nephritis (English)

1 reference

25 August 2017

2

Kosaku Nitta

1 reference

25 August 2017

Keiko Uchida

1

1 reference

25 August 2017

publication date

8 November 2011

1 reference

Clinical and experimental nephrology

25 August 2017

published in

1 reference

25 August 2017

volume

16

1 reference

25 August 2017

issue

2

1 reference

25 August 2017

page(s)

202-213

1 reference

Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Human clinical trials in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus--results from LUMINA (LIX): a multiethnic US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Antiproteinuric effect of angiotensin-converting enzyme inhibitors and an angiotensin II receptor blocker in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

The role of aldosterone blockade in murine lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Cyclophosphamide in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Pharmacokinetics of orally administered tacrolimus in lupus nephritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Intravenous methylprednisolone or plasma exchange for adjunctive therapy of severe renal vasculitis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Long-term mizoribine intermittent pulse therapy for young patients with flare of lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome : workshop recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Methotrexate therapy in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Biologics in the treatment of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Block and tackle: CTLA4Ig takes on lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Biologics as treatment for systemic lupus: great efforts, sobering results, new challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

The classification of glomerulonephritis in systemic lupus erythematosus revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-011-0556-4

Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis

21 January 2018

1 reference

12 December 2020

High-dose mizoribine treatment for adolescents with systemic lupus erythematosus

1 reference

12 December 2020

A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group

1 reference

12 December 2020

Clinical assessment of tacrolimus therapy in lupus nephritis: one-year follow-up study in a single center

1 reference

12 December 2020

Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose.

1 reference

12 December 2020

Use of methotrexate in patients with systemic lupus erythematosus and primary Sjögren's syndrome

1 reference

12 December 2020

Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study

1 reference

12 December 2020

Minimal change disease in systemic lupus erythematosus

1 reference

12 December 2020

Randomised trial of plasma exchange in mild systemic lupus erythematosus

1 reference

12 December 2020

Tacrolimus is effective for lupus nephritis patients with persistent proteinuria.

1 reference

12 December 2020

Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group.

1 reference

12 December 2020

Practice pattern variation in oral glucocorticoid therapy after the induction of response in proliferative lupus nephritis.

1 reference

12 December 2020

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response

1 reference

12 December 2020

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

12 December 2020

Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis.

1 reference

12 December 2020

K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease

1 reference

12 December 2020

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial

1 reference

12 December 2020

10.1007/S10157-011-0556-4

Identifiers

DOI

1 reference

25 August 2017

1 reference